tirzepatide discovery Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology Read now: The SURPASS-EARLY trial

In patients with T2D who need greater glucose lowering than can be obtained with oral agents, GLP-1 RAs are preferred to insulin when possible

Here are 8 potential reasons why not to prescribe Lixisenatide: 1- this is only one small study and only one dose was tested, 2- Lixisenatide is not currently available at pharmacies, 3- the weight loss associated with this GLP-1 is not desirable in many cases of Parkinsons disease where weight loss is an issue, 4- non-motor outcomes did not change as in other trials, and this will need to be better explained

ozempic , 2

The study concludes: "Preliminary findings support the effectiveness of daily liposomal GSH [reduced glutathione] administration at elevating stores of GSH and impacting immune function and levels of oxidative stress." (Source 1) Additionally, the study showed that both doses (500 mg and 1000 mg) seemed to work equally well, suggesting the benefits of liposomal glutathione, even at lower doses

Evening Injection: Potential Advantages and Considerations Injecting semaglutide before bed offers logistical convenience for people with busy daytime schedules

Impact of long-term RF-EMF on oxidative stress and neuroinflammation in aging brains of C57BL/6 mice